Pasritamig targets KLK2 and has FDA fast track designation for mCRPC, enabling accelerated development and review processes. Phase 1 study showed pasritamig was well-tolerated with promising antitumor ...

Enzalutamide plus ADT significantly reduced the risk of radiographic progression or death and castration resistance compared to darolutamide plus ADT in mHSPC patients. The MAIC analysis provided a ...

Pembrolizumab plus axitinib showed superior overall survival and progression-free survival compared to sunitinib in advanced clear cell renal cell carcinoma. The combination therapy demonstrated a ...

"This announcement is an important step in increasing the awareness and accessibility of OnQ Prostate beyond its earliest adopters, so that more physicians and patients can benefit from this ...

The updated guideline emphasizes a patient-centered, risk-based approach, prioritizing symptom resolution and antimicrobial stewardship over microbial eradication. New recommendations include ...

In this episode, host Adam B. Weiner, MD, is joined by Maarten Albersen, MD, PhD, for a focused discussion on the evolving molecular landscape of penile cancer. The FDA Oncologic Drugs Advisory ...

PSMA-targeted T-cell engager enters phase 1 testing in mCRPC ...

Investigators reported that the treatment-emergent adverse event results showed combination tamsulosin and mirabegron was well-tolerated and had a favorable safety profile. Adding mirabegron ...

Cycling has multiple benefits, and steps can be taken to prevent genitourinary injury. Bicycling across the globe is increasing as a means of exercise and transportation. Clinicians need to be ...

In a retrospective study of almost 500 men, the use of hyaluronic acid filler for penile girth enhancement appeared safe with limited adverse events. Using the PhalloFILL system, a novel hyaluronic ...

The decline in total testosterone was observed even among men with normal body mass index. From 1999 to 2016, testosterone levels have declined in adolescent and young adult men (AYA), according to ...

LiSWT and PRP independently and combined significantly improved IIEF scores in ED treatment compared to control therapy. LiSWT was the most effective standalone treatment, with a mean IIEF score ...